IRVING, Texas, July 15, 2008 (PRIME NEWSWIRE) -- DelSite, Inc. (OTCBB:CARN) announced that its GelVac(tm) intranasal powder platform was successfully used in achieving systemic delivery of arginine-vasopressin (AVP), an off-patent peptide therapeutic for controlling urine volume. AVP is normally administered as an injection or as a liquid nasal spray and has a worldwide market of approximately 300 million dollars.
